Piper Jaffray analyst Joshua Schimmer said the the Phase 3 trial of GW Pharmaceuticals' Epidiolex in Lennox-Gastaut Syndrome, or LGS, demonstrated a "robust" median seizure reduction and an acceptable and well-tolerated safety profile, which is another important success which, along with its Dravet Syndrome data, positions the company for regulatory approval pending additional trial readouts. The company has a pre-NDA meeting scheduled with the FDA soon to discuss the DS data and NDA submission, and plans to request one now for LGS, noted Schimmer, who keeps an Overweight rating and $147 price target on GW shares.